Betamethasone dipropionate/calcipotriol microarray patch - LEO Pharma/Lohmann Therapie Systeme
Alternative Names: Betamethasone dipropionate/calcipotriol micro needle patch- LEO pharma/Lohmann Therapie Systeme; Calcipotriol/betamethasone dipropionate microarray patch; Calipotriol/betamethasone dipropionate micro needle patchLatest Information Update: 28 Apr 2023
At a glance
- Originator LEO Pharma; Lohmann Therapie-Systeme
- Class Anti-inflammatories; Antiallergics; Antipsoriatics; Cyclohexenes; Dihydroxycholecalciferols; Fluorinated steroids; Glucocorticoids; Indenes; Small molecules; Vitamin D analogues
- Mechanism of Action Calcitriol receptor agonists; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Plaque psoriasis; Psoriasis
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Psoriasis in Denmark (Intradermal, Patch)
- 28 May 2022 No recent reports of development identified for phase-I development in Plaque-psoriasis in Germany (Intradermal, Patch)
- 29 Oct 2019 LEO Pharma completes a phase I trial in plaque-psoriasis in Germany (Intradermal) (NCT03898583)